341028-37-3
341028-37-3 结构式
基本信息
4,5-二甲基-3-(2-氧代-2-苯乙基)-噻唑氯化物
4,5-二甲基-3-(2-氧代-2-苯基乙基)噻唑氯化物
4,5-dimethyl-3-(2-oxo-2-phenylethyl)thiazolium chloride
alagebrium chloride
ALT-711
Dimethyl-3-(2-oxo-2-phenyl)-chloride
(Alagebrium) (thiazolium salt)
物理化学性质
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/04/30 | XW0234102837303 | 4,5-二甲基-3-(2-氧代-2-苯基乙基)噻唑氯化物 | 341028-37-3 | 1G | 88元 |
| 2024/04/30 | XW0234102837304 | 4,5-二甲基-3-(2-氧代-2-苯基乙基)噻唑氯化物 | 341028-37-3 | 5G | 339元 |
| 2024/04/30 | HY-106024B | 4,5-二甲基-3-(2-氧代-2-苯基乙基)噻唑氯化物 Alagebrium chloride | 341028-37-3 | 200mg | 500元 |
常见问题列表
AGE
Alagebrium chloride is an advanced glycation end product ( AGE ) inhibitor. Endothelial cell (EC) proliferation is increased for all groups receiving Alagebrium (ALT-711), particularly when seeded on matrix from the AAo of obese (ZO) and diabetic (ZD) rats.
Blood pressure is not affected by treatment with Alagebrium. In diabetic RAGE apoE double-KO mice, treatment with Alagebrium is associated with a modest reduction in renal mass and reduces hyperfiltration compare with nontreated mice. Treatment with Alagebrium in diabetic RAGE apoE double-KO mice is associated with a further reduction in glomerular collagen IV levels, approaching levels observed in control mice. Body weight, heart rate (HR), and mean blood pressure (BP) are similar in Zucker lean (ZL), obese (ZO), and diabetic (ZD) groups in the absence or presence of Alagebrium (ALT-711). Alagebrium increases blood flow (BF) in ZO rats but reduces distal vascular resistance in ZD rats. A decrease in neointimal hyperplasia (NH) intrastrut thickness as a function of local radius is found in all groups with Alagebrium treatment. A significant increase in TGF-β expression is also found in the AAo of ZL rats treated with Alagebrium.